Gain Therapeutics Files 8-K
Ticker: GANX · Form: 8-K · Filed: Jul 9, 2024 · CIK: 1819411
| Field | Detail |
|---|---|
| Company | Gain Therapeutics, Inc. (GANX) |
| Form Type | 8-K |
| Filed Date | Jul 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulatory
TL;DR
Gain Therapeutics just dropped an 8-K, check it for updates.
AI Summary
Gain Therapeutics, Inc. filed an 8-K on July 9, 2024, reporting an event under Regulation FD Disclosure and Other Events. The filing includes financial statements and exhibits. The company is incorporated in Delaware and headquartered in Bethesda, Maryland.
Why It Matters
This 8-K filing indicates that Gain Therapeutics is disclosing material information to the public, which could impact investor understanding of the company's current status and future prospects.
Risk Assessment
Risk Level: low — This filing is a standard 8-K disclosure and does not inherently indicate significant new risks.
Key Numbers
- 001-40237 — SEC File Number (Identifies the company's filing with the SEC.)
- 85-1726310 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Gain Therapeutics, Inc. (company) — Registrant
- July 9, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Bethesda, Maryland (location) — Principal executive offices
FAQ
What specific event triggered this 8-K filing?
The filing indicates it is for Regulation FD Disclosure and Other Events, but the specific event is not detailed in the provided text.
What type of financial statements are included?
The filing states that 'Financial Statements and Exhibits' are included, but the specific nature of these statements is not detailed in the provided text.
Where is Gain Therapeutics, Inc. headquartered?
Gain Therapeutics, Inc. is headquartered at 4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on July 9, 2024.
What is the company's SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 580 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-07-09 17:18:46
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value GANX The NASDAQ Stock Marke
Filing Documents
- tm2419145d1_8k.htm (8-K) — 28KB
- tm2419145d1_ex99-1.htm (EX-99.1) — 13KB
- 0001104659-24-078600.txt ( ) — 218KB
- ganx-20240709.xsd (EX-101.SCH) — 3KB
- ganx-20240709_lab.xml (EX-101.LAB) — 33KB
- ganx-20240709_pre.xml (EX-101.PRE) — 22KB
- tm2419145d1_8k_htm.xml (XML) — 4KB
01
Item 7.01. Regulation FD Disclosure. On July 9, 2024, Gain Therapeutics, Inc. (the "Company") issued a press release announcing the completion of dosing in the multiple ascending dose (MAD) of its Phase 1 study of GT-02287, a novel small molecule therapy for Parkinson's Disease. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
01
Item 8.01. Other Events. On July 9, 2024, the Company announced the completion of dosing in the multiple ascending dose (MAD) of its Phase 1 study of GT-02287, a novel small molecule therapy for Parkinson's Disease. No discontinuations or serious adverse events were reported.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) The following Exhibit 99.1 is furnished with this report: Exhibit No. Description 99.1 Gain Therapeutics, Inc. Press Release dated July 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GAIN THERAPEUTICS, INC. Date: July 9, 2024 By: /s/ Gene Mack Name: Gene Mack Title: Chief Financial Officer